These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 23774940)

  • 1. Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study.
    Ciccacci C; Di Fusco D; Marazzi MC; Zimba I; Erba F; Novelli G; Palombi L; Borgiani P; Liotta G
    Eur J Clin Pharmacol; 2013 Nov; 69(11):1909-16. PubMed ID: 23774940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of glutathione transferases genes polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN susceptibility.
    Ciccacci C; Latini A; Politi C; Mancinelli S; Marazzi MC; Novelli G; Palombi L; Borgiani P
    Eur J Clin Pharmacol; 2017 Oct; 73(10):1253-1259. PubMed ID: 28689274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacogenetics study in Mozambican patients treated with nevirapine: full resequencing of TRAF3IP2 gene shows a novel association with SJS/TEN susceptibility.
    Ciccacci C; Rufini S; Mancinelli S; Buonomo E; Giardina E; Scarcella P; Marazzi MC; Novelli G; Palombi L; Borgiani P
    Int J Mol Sci; 2015 Mar; 16(3):5830-8. PubMed ID: 25775161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HCP5 genetic variant (RS3099844) contributes to Nevirapine-induced Stevens Johnsons Syndrome/Toxic Epidermal Necrolysis susceptibility in a population from Mozambique.
    Borgiani P; Di Fusco D; Erba F; Marazzi MC; Mancinelli S; Novelli G; Palombi L; Ciccacci C
    Eur J Clin Pharmacol; 2014 Mar; 70(3):275-8. PubMed ID: 24322967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multivariate genetic analysis confirms rs5010528 in the human leucocyte antigen-C locus as a significant contributor to Stevens-Johnson syndrome/toxic epidermal necrolysis susceptibility in a Mozambique HIV population treated with nevirapine.
    Ciccacci C; Politi C; Mancinelli S; Ciccacci F; Lucaroni F; Novelli G; Marazzi MC; Palombi L; Borgiani P
    J Antimicrob Chemother; 2018 Aug; 73(8):2137-2140. PubMed ID: 29762688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations.
    Carr DF; Chaponda M; Cornejo Castro EM; Jorgensen AL; Khoo S; Van Oosterhout JJ; Dandara C; Kampira E; Ssali F; Munderi P; Lalloo DG; Heyderman RS; Pirmohamed M
    J Antimicrob Chemother; 2014 Dec; 69(12):3329-34. PubMed ID: 25147095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique.
    Ciccacci C; Borgiani P; Ceffa S; Sirianni E; Marazzi MC; Altan AM; Paturzo G; Bramanti P; Novelli G; Palombi L
    Pharmacogenomics; 2010 Jan; 11(1):23-31. PubMed ID: 20017669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.
    Heil SG; van der Ende ME; Schenk PW; van der Heiden I; Lindemans J; Burger D; van Schaik RH
    Ther Drug Monit; 2012 Apr; 34(2):153-9. PubMed ID: 22354160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.
    Dickinson L; Chaponda M; Carr DF; van Oosterhout JJ; Kumwenda J; Lalloo DG; Pirmohamed M; Heyderman RS; Khoo SH
    Antimicrob Agents Chemother; 2014; 58(2):706-12. PubMed ID: 24217698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.
    Fagot JP; Mockenhaupt M; Bouwes-Bavinck JN; Naldi L; Viboud C; Roujeau JC;
    AIDS; 2001 Sep; 15(14):1843-8. PubMed ID: 11579247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
    Saitoh A; Sarles E; Capparelli E; Aweeka F; Kovacs A; Burchett SK; Wiznia A; Nachman S; Fenton T; Spector SA
    AIDS; 2007 Oct; 21(16):2191-9. PubMed ID: 18090046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population.
    Carr DF; Bourgeois S; Chaponda M; Takeshita LY; Morris AP; Castro EM; Alfirevic A; Jones AR; Rigden DJ; Haldenby S; Khoo S; Lalloo DG; Heyderman RS; Dandara C; Kampira E; van Oosterhout JJ; Ssali F; Munderi P; Novelli G; Borgiani P; Nelson MR; Holden A; Deloukas P; Pirmohamed M
    J Antimicrob Chemother; 2017 Apr; 72(4):1152-1162. PubMed ID: 28062682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices.
    Calcagno A; D'Avolio A; Simiele M; Cusato J; Rostagno R; Libanore V; Baietto L; Siccardi M; Bonora S; Di Perri G
    Br J Clin Pharmacol; 2012 Jul; 74(1):134-40. PubMed ID: 22680342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of nevirapine-associated Stevens-Johnson syndrome among HIV-infected pregnant women: the Medunsa National Pharmacovigilance Centre, 2007 - 2012.
    Dube N; Adewusi E; Summers R
    S Afr Med J; 2013 May; 103(5):322-5. PubMed ID: 23971123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: a multicentric study in four countries.
    Saka B; Barro-Traoré F; Atadokpédé FA; Kobangue L; Niamba PA; Adégbidi H; Yedomon HG; Traoré A; Pitché VP
    Int J Dermatol; 2013 May; 52(5):575-9. PubMed ID: 23330601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic predictors of nevirapine pharmacokinetics in Ghanaian children living with HIV with or without TB coinfection.
    Langaee T; Al-Shaer MH; Gong Y; Lima E; Antwi S; Enimil A; Dompreh A; Yang H; Alghamdi WA; Wiesner L; Peloquin CA; Kwara A
    Infect Genet Evol; 2021 Aug; 92():104856. PubMed ID: 33839311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific association of the rs6500265 and rs9933632 single-nucleotide polymorphisms in Japanese patients with antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements.
    Okamoto-Uchida Y; Nakamura R; Matsunaga K; Aihara M; Saito Y
    Pharmacogenet Genomics; 2018 Mar; 28(3):95-98. PubMed ID: 29239905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)-induced Stevens-Johnson syndrome and gynecomastia in an HIV-infected child: A case report.
    Saka B; Akakpo AS; Bassowa A; Dapam AN; Mahamadou G; Teclessou JN; Mouhari-Toure A; Laouali AY; Mensah E; Kombaté K; Pitché P
    Ann Dermatol Venereol; 2018 Dec; 145(12):773-776. PubMed ID: 30301570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.
    Schipani A; Wyen C; Mahungu T; Hendra H; Egan D; Siccardi M; Davies G; Khoo S; Fätkenheuer G; Youle M; Rockstroh J; Brockmeyer NH; Johnson MA; Owen A; Back DJ;
    J Antimicrob Chemother; 2011 Jun; 66(6):1332-9. PubMed ID: 21441248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine.
    Metry DW; Lahart CJ; Farmer KL; Hebert AA
    J Am Acad Dermatol; 2001 Feb; 44(2 Suppl):354-7. PubMed ID: 11174414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.